BioPorto

BioPorto 是一家在股票代码 BIOPOR (DK) 下上市的公司。

查看带有其 15 名主要高管的组织结构图

BioPorto 搜索最多的简介

• Peter Mørch Eriksen, Chief Executive Officer
• John McDonough, Chairman of the Board (leaving)
• Don Hardison, Vice Chairman of the Board

高管在BioPorto变化

• John McDonough, Chairman of the Board 请很快离开公司  (新闻发布的2024十二月18号).
• Niels Høy NielsenNiels Høy Nielsen 将于20248月1作为 Executive Vice President and Chief Financial Officer 加入公司  (新闻发布的2024五月31号).
• Jeffrey Haas已作为President and Chief Executive Officer, US加入公司  (新闻发布的2024五月8号).

更多的变化在％s

创建提醒
跟踪 BioPorto 的高管变动

BioPorto 拥有 2,333 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。

Popular M&A news in 生物技术

• Deerfield has announced the acquisition of Singular Genomics  (公布2024十二月24号).
• Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
• OraSure Technologies has announced the acquisition of Sherlock Biosciences  (公布2024十二月20号).

生物技术 行业的其他推荐联系人

• Scholar Rock 企业 Kristina Burow - Director
• VBI Vaccines 企业 Steven Gillis - Chairman of the Board
• Adaptimmune Therapeutics 企业 Ali Behbahani - Non-Executive Director

了解更多有关生物技术行业的信息 >

BioPorto 的最新新闻稿

• First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
• BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study
• BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
• Correction: BioPorto Announces Annual Results for 2023
• BioPorto A/S Appoints Chief Legal Officer
• BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
• BioPorto Provides a Business Update
• News - Bioporto
• View more press releases Close

关于 BioPorto 的社交媒体

• BioPorto 在 维基百科、谷歌新闻 和 雅虎财经
• BioPorto 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Henrik Juuel

致电BioPorto，电话：+45 ...

查看组织结构图

Register to receive your alert

报告错误